Want to see ADAG full AI Analyst Report?
ADAG Stock Chart & Stats
$3.97
-$0.15(-7.28%)
At close: 4:00 PM EST
$3.97
-$0.15(-7.28%)
Day’s Range― - ―
52-Week Range$1.30 - $4.85
Previous CloseN/A
Volume1.51K
Average Volume (3M)289.80K
Market Cap
$174.38M
Enterprise Value$37.85
Total Cash (Recent Filing)$74.52M
Total Debt (Recent Filing)$6.26M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Sep 02, 2026EPS Estimate
-0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding66,072,590
10 Day Avg. Volume294,932
30 Day Avg. Volume289,800
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)2.02
Price to Sales (P/S)9.30
P/FCF Ratio-4.55
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside126.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.71
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Proprietary Discovery PlatformAdagene’s proprietary antibody discovery and engineering platforms provide durable competitive advantages for generating differentiated therapeutic candidates. Platform-driven discovery can lower long-term R&D costs per program, enable faster iteration across multiple assets, and support licensing or partnership economics that persist beyond single trial outcomes.
Partnership-driven Revenue ModelRelying on collaborations and partnerships creates recurring non-product revenue channels (upfronts, milestones, R&D service fees, royalties). For a clinical-stage biotech, this model reduces sole dependence on biotech commercialization, spreads program risk, and provides durable financing and validation through partner-funded development.
Strengthened Near-term LiquidityA disclosed cash balance of ~$127.9M materially improves operational runway in the near-to-mid term and lowers immediate financing pressure. Sizable cash reserves support ongoing trials, platform investment, and partnership execution, reducing short-term dilution risk and enabling strategic optionality while clinical programs advance.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow indicates the business is not yet self-sustaining and will remain reliant on external funding until commercial revenues or material milestones occur. Ongoing burn pressures governance on program prioritization and increases the probability of future equity or debt raises that can dilute shareholders or constrain strategy.
Volatile Revenue And Gross ProfitLarge swings in revenue and a history of negative gross profit highlight unpredictability in collaboration timing and cost recognition. This volatility undermines confidence in sustainable top-line growth and margin stability, complicating multi-period planning and making recurring cash generation from operations uncertain until revenue streams stabilize.
Ongoing Losses And Funding RiskMulti-year operating and net losses mean returns on capital remain negative, increasing the risk that management must access capital markets or partners to continue development. Elevated funding and execution risk can slow program timelines, increase dilution risk, and pressure strategic choices if cash generation fails to improve materially.
Adagene News
ADAG FAQ
What was Adagene, Inc.’s price range in the past 12 months?
Adagene, Inc. lowest stock price was $1.30 and its highest was $4.85 in the past 12 months.
What is Adagene, Inc.’s market cap?
Adagene, Inc.’s market cap is $174.38M.
When is Adagene, Inc.’s upcoming earnings report date?
Adagene, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 41 days.
How were Adagene, Inc.’s earnings last quarter?
Adagene, Inc. released its earnings results on Apr 01, 2026. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.1 by $0.02.
Is Adagene, Inc. overvalued?
According to Wall Street analysts Adagene, Inc.’s price is currently Undervalued.
Does Adagene, Inc. pay dividends?
Adagene, Inc. does not currently pay dividends.
What is Adagene, Inc.’s EPS estimate?
Adagene, Inc.’s EPS estimate is -0.19.
How many shares outstanding does Adagene, Inc. have?
Adagene, Inc. has 66,072,590 shares outstanding.
What happened to Adagene, Inc.’s price movement after its last earnings report?
Adagene, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.1. Following the earnings report the stock price went down -13.449%.
Which hedge fund is a major shareholder of Adagene, Inc.?
Currently, no hedge funds are holding shares in ADAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Adagene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (126.70% Upside)
$9.00 (126.70% Upside)
Blogger Sentiment
Bullish
ADAG Sentiment 70%
Sector Average 66%
Sector Average 66%
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.5%
Last 30 Days ▲ 1.2%
Last 30 Days ▲ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
90.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-12.33%
Trailing 12-Months
Company Description
Adagene, Inc.
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
ADAG Stock 12 Month Forecast
Average Price Target
$9.00
▲(126.70% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.02% Mutual Funds
3.72% Other Institutional Investors
96.20% Public Companies and
Individual Investors